New research suggests that patients who come off new GLP-1 drugs like semaglutide or tirzepatide can put back on shed pounds at a significantly accelerated pace than those who halt traditional diet and exercise plans.
Findings released in a major medical journal points out that while obese people can lose substantial amounts of their total mass while on the medication, the mass is regained at an estimated rate of nearly a kilo each month once they quit.
"Individuals purchasing such medications should be aware of the danger of fast weight regain when the therapy is stopped," cautioned lead investigator Dr. Susan Jebb.
This pace of recovery implies a reversion to pre-treatment weight within about a year and a half.
Analyzing Treatments
The research, which reviewed dozens of studies involving thousands of participants, compared the effects of GLP-1 agonists with other pills.
Scientists point out that people who shed pounds through diet and exercise usually have a more gradual creep back—approximately 100 grams monthly—post-intervention.
Explaining the Rapid Rebound
Experts suggest the way of the drugs explains the accelerated weight return.
The injections mimic a natural hormone called GLP-1, which controls hunger.
"Sustained high doses of GLP-1 concentrations several times higher than the body's typical production could lead to the body to produce less of its endogenous GLP-1, and may also lessen responsiveness to its actions," said Dr. Adam Collins, a dietetics researcher.
"Withdrawal of this GLP-1 'fix' means appetite is no longer kept in check, making overeating a significant risk."
An Ongoing Condition?
The NHS advise the jabs for individuals with obesity-related health risks, accompanied by prescribed diet and exercise modifications.
A number of clinicians contend that, given the likelihood of weight regain, the treatment might need to be ongoing.
This view is supported by drug manufacturers, who state that the findings "emphasize the long-term nature of excess weight," comparing it to managing diseases like diabetes.
Patient Accounts
Individuals who have discontinued the jabs explain a intense resurgence of cravings.
"It felt as if something flipping and I was suddenly ravenous," recalled a patient.
This challenge is exacerbated if patients have not adopted permanent dietary or behavioural modifications during treatment.
Widespread Adoption
Figures suggest that millions of adults in the UK have tried these injections in the past year, with interest remaining high.
- Adoption is higher among women compared to men.
- The 40s and 50s demographic shows the greatest level of interest.
- Many obtain the medications through private healthcare rather than public health services.
Ultimately, researchers stress that while these medications are effective agents for weight loss, they are not a permanent solution and lasting health benefits likely depends on ongoing behavioural management.
